| Name | Loxoprofen |
| Description | Loxoprofen (Koloxo) is an anti-inflammatory non-steroidal medicine. |
| Cell Research | To determine the proliferation of LLC cells with or without Loxoprofen, 2×104 cells are seeded into 100-mm dishes containing 10 ml culture medium supplemented with 50 μg/ml Loxoprofen or vehicle on day 0. On days 2, 3, 4 and 6, the cells are trypsinized and counted. (Only for Reference) |
| In vitro | Loxoprofen sodium(LOX) does not affect the proliferation and viability of LLC cells in vitro. HUVECs treated with LOX results in the inhibition of the tubular formation. Treatment with 50 mg/ml LOX reveals a 33% decline in in vitro angiogenesis, compared with vehicle-treated HUVECs. This inhibition is presumably due to inhibition of VEGF activity[1]. |
| In vivo | Loxoprofen sodium (LOX), inhibits in vivo growth of implanted Lewis lung carcinoma (LLC). Intratumoral vessel density in LOX-treated mice is significantly lower than that of mice without treatment. Intratumoral expressions of vascular endothelial growth factor (VEGF) mRNA are attenuated by the LOX treatment. LOX suppresses both intratumoral and systemic VEGF protein in LLC-implanted mice. LOX also inhibits tubular formation of primary cultured human umbilical vein endothelial cells, presumably due to the inhibition of VEGF. In patients with advanced non-small cell lung cancer, LOX medication (120 mg/day) for a week significantly decreases the plasma VEGF level[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (203 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 46 mg/mL (186.76 mM), Sonication is recommended.
|
| Keywords | VEGF | pain | NSAID | Loxoprofen | LLC | Inhibitor | inhibit | inflammation | HUVECs | Cyclooxygenase | COX | atherosclerosis | analgesic |
| Inhibitors Related | Bismuth Subsalicylate | Phenacetin | Ibuprofen | Acetaminophen | Salicylamide | Diclofenac sodium | Diclofenac Potassium | Paradol | Indomethacin sodium hydrate | Salicylic acid | Glafenine | Revaprazan hydrochloride |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Fibrosis Compound Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Human Metabolite Library | Anti-Cancer Drug Library |
United States
